C2N Diagnostics has announced that pharmaceutical company Eisai has agreed to invest up to $15 million in C2N to provide broader access to Alzheimer's disease tests.
Eisai's investment is intended to support C2N's efforts to expand the availability, accessibility, and use of its Precivity blood-based biomarker tests for the early diagnosis of Alzheimer's disease in the U.S.
In 2022, the two companies signed an agreement to build awareness of the benefits of blood-based assays for cognitive impairment, including Alzheimer's disease.
C2N’s Precivity tests use mass spectrometry to measure two plasma proteins implicated in the Alzheimer's disease process, tau and amyloid beta (Aβ). Eisai is the manufacturer of Leqembi, an Aβ-directed antibody that has been approved by the U.S. Food and Drug Administration for the treatment of Alzheimer's disease.
"We greatly appreciate the dedication and thoroughness Eisai brought to evaluating the value and quality of our advanced diagnostic solutions in the field of brain health," Dr. Joel Braunstein, C2N's CEO said. "With this financing, we're building on our history of attracting the highest-quality investors committed to changing the trajectory of Alzheimer's disease through early detection and treatment and, ultimately, prevention. We're proud to have Eisai's leadership in the field as we're transforming the management and clinical care standard for patients with Alzheimer's disease."
